NASDAQ · Biotechnology · USD
Korsana Biosciences, Inc. (KRSA) Stock Analysis
Korsana Biosciences, Inc. (KRSA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
KRSA Key Statistics
As of Oct 21, 2026Trading
- Open
- $30.02
- Previous Close
- $31.03
- Day's Range
- 29.78–32.75
- 52-Week Range
- 7.19–59.36
- Volume
- 129.77K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.73
Valuation
- Market Cap
- $1.48B
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −7.07
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$35.64M
- Shares Outstanding
- 45.54M
- 1-Year Return
- +115.21%
Dividend and dates
- Avg Volume
- 50.63K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, KRSA closed at $32.54, +115.21% over 1 year.
Korsana Biosciences, Inc. (KRSA) has a market capitalization of $1.48B.
In fiscal 2025, KRSA reported revenue of $0.00.
KRSA Stock Return by Calendar Year
Korsana Biosciences, Inc. (KRSA) return since Mar 2019: what $10,000 became
- 1 year
- $10,000 $21,521
- +115.21%
- 5 years
- $10,000 $833
- −91.67%
- Since Mar 2019
- $10,000 $186
- −98.14%
If you had invested $10,000 in Korsana Biosciences, Inc. (KRSA) at the close on March 18, 2019, the earliest close on record here, it would have been worth $186 at the close on October 21, 2026: −98.14% in total, −40.83% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +266.03% |
| 2025 | −60.56% |
| 2024 | −3.88% |
| 2023 | −74.47% |
| 2022 | −61.86% |
| 2021 | −43.79% |
| 2020 | +12.50% |
| 2019 (partial year) | −78.24% |
As of October 21, 2026.
KRSA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$35.64M | — |
| 2024 | $0.00 | −$88.00K | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$37.29M | −$35.64M | — |
| 2024 | $0.00 | — | −$109.00K | −$88.00K | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Wedbush Initiates Coverage On Korsana Biosciences with Outperform Rating, Announces Price Target of $44
BenzingaKorsana Biosciences (KRSA) At $31.20 Leaves Valuation Questions On A Sharp 2026 Run
YahooGuggenheim Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $70
BenzingaStifel Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $43
BenzingaTD Cowen Initiates Coverage On Korsana Biosciences with Buy Rating
BenzingaUBS Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $55
Benzinga
All 7 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B